# Traws Pharma, Inc. clinical trials: 35 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Traws Pharma, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Traws Pharma, Inc.: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/traws-pharma-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 13, 2026 | NCT07526506 | Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers | Traws Pharma, Inc. | Phase 1 | Recruiting | Healthy Volunteer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526506) |
| March 31, 2026 | NCT07503405 | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Traws Pharma, Inc. | Phase 2 | Not yet recruiting | Influenza | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503405) |
| January 28, 2026 | NCT07371650 | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate... | Traws Pharma, Inc. | Phase 2 | Active not recruiting | Influenza | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371650) |
| September 5, 2025 | NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | Traws Pharma, Inc. | Phase 2 | Completed | COVID - 19 | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07157007) |
| January 3, 2025 | NCT06757738 | A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers | Traws Pharma, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06757738) |
| May 7, 2024 | NCT06402136 | Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers | Traws Pharma, Inc. | Phase 1 | Completed | Healthy Volunteers Only | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06402136) |
| January 30, 2023 | NCT05705505 | Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies | Traws Pharma, Inc. | Phase 1/2 | Unknown | Endometrioid Endometrial Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05705505) |
| February 4, 2021 | NCT04739293 | Study of ON 123300 in Patients With Advanced Cancer | Traws Pharma, Inc. | Phase 1 | Unknown | Solid Tumors, Adult | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04739293) |
| September 29, 2015 | NCT02562443 | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | Traws Pharma, Inc. | Phase 3 | Terminated | Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02562443) |
| June 20, 2014 | NCT02168725 | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | Traws Pharma, Inc. | Phase 1 | Terminated | Neoplasms, Advanced Solid Tumor | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02168725) |
| April 8, 2014 | NCT02107235 | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | Traws Pharma, Inc. | Phase 1 | Completed | Head and Neck Neoplasms, Carcinoma, Squamous Cell | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02107235) |
| March 3, 2014 | NCT02075034 | Three Dosing Schedules of Oral Rigosertib in MDS Patients | Traws Pharma, Inc. | Phase 1 | Withdrawn | Myelodysplastic Syndrome | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02075034) |
| January 8, 2014 | NCT02030639 | Metabolism and Excretion of \[14C\]-Rigosertib After Infusion to Volunteers | Traws Pharma, Inc. | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02030639) |
| August 26, 2013 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | Traws Pharma, Inc. | Phase 3 | Completed | Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01928537) |
| August 21, 2013 | NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | Traws Pharma, Inc. | Phase 1/2 | Completed | Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01926587) |
| July 22, 2013 | NCT01904682 | Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs | Traws Pharma, Inc. | Phase 2 | Completed | Myelodysplastic Syndromes | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01904682) |
| March 8, 2013 | NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | Traws Pharma, Inc. | Phase 2 | Completed | Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous... | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01807546) |
| April 25, 2012 | NCT01584531 | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | Traws Pharma, Inc. | Phase 2 | Completed | Myelodysplastic Syndrome, MDS, Trisomy 8 | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01584531) |
| February 24, 2012 | NCT01538563 | Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | Traws Pharma, Inc. | Phase 1 | Completed | Solid Tumors, Advanced Cancer, Cancer, Neoplasms | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01538563) |
| February 24, 2012 | NCT01538537 | Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer | Traws Pharma, Inc. | Phase 1 | Completed | Advanced Cancer, Solid Tumors, Cancer, Neoplasms | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01538537) |
| May 26, 2011 | NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer | Traws Pharma, Inc. | Phase 3 | Completed | Metastatic Pancreatic Adenocarcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01360853) |
| November 16, 2010 | NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | Traws Pharma, Inc. | Phase 3 | Completed | Myelodysplastic Syndromes, MDS, RAEB, Chronic Myelomonocytic Leukemia | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01241500) |
| July 22, 2010 | NCT01168011 | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors | Traws Pharma, Inc. | Phase 1 | Completed | Solid Tumor | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01168011) |
| July 22, 2010 | NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | Traws Pharma, Inc. | Phase 1/2 | Completed | Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease, Chronic Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01167166) |
| July 20, 2010 | NCT01165905 | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | Traws Pharma, Inc. | Phase 1 | Completed | Solid Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01165905) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 5 |
| Phase 2 | 8 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 25 |
| Terminated | 3 |
| Withdrawn | 2 |
| Unknown | 2 |
| Recruiting | 1 |
| Not yet recruiting | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myelodysplastic Syndromes | 12 |
| Neoplasms | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia, Myelomonocytic, Chronic | 3 |
| Influenza, Human | 3 |
| Anemia, Refractory, with Excess of Blasts | 3 |
| Chromosome 8, trisomy | 2 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Head and Neck Neoplasms | 2 |
| Carcinoma, Squamous Cell | 2 |
| Cytopenia | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Leukemia | 1 |
| Ovarian Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
| Pancreatic Neoplasms | 1 |
| Lymphoma | 1 |
| Burkitt Lymphoma | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Anus Neoplasms | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| COVID-19 | 1 |
| Anemia, Refractory | 1 |
| Myeloproliferative Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Psychology practices in the United States](https://specstream.ai/data/businesses/psychology-practices/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
- [Tapas bars in the United States](https://specstream.ai/data/businesses/tapas-bars/united-states)
- [Vehicle manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-manufacturers/united-states)
- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
- [B2B environmental companies in the United States](https://specstream.ai/data/businesses/b2b-environmental-companies/united-states)
